<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50334">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01972529</url>
  </required_header>
  <id_info>
    <org_study_id>E5501-G000-310</org_study_id>
    <secondary_id>2013-000965-34</secondary_id>
    <nct_id>NCT01972529</nct_id>
  </id_info>
  <brief_title>Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure</brief_title>
  <official_title>A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <authority>European Union: European Medicines Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel group
      study using avatrombopag to treat adults with thrombocytopenia associated with liver
      disease. The study will evaluate avatrombopag in the treatment of thrombocytopenia
      associated with liver disease prior to an elective procedure to reduce the need for platelet
      transfusions or any rescue procedure for bleeding due to procedural and post-procedural
      bleeding complications. Subjects will be enrolled into 2 cohorts according to mean baseline
      platelet count and, within each baseline platelet count cohort will be further stratified by
      risk of bleeding associated with the elective procedure (low, moderate, or high) and
      hepatocellular carcinoma (HCC) status (Yes or No).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will consist of 3 phases: Prerandomization, Randomization, and a Follow-up Phase.
      The Prerandomization Phase includes one Screening Visit that will take place from Day -14
      through Day -1; the Randomization Phase includes the Baseline Period, Treatment Period, and
      Procedure Day Period (5 to 8 days after last dose of study drug [Study Day 10 to 13]). The
      Follow-up Phase comprises 2 visits: 7 days post Procedure Day and 30 days after receiving
      the last dose of study drug. Permitted procedures include: Dental procedures; Paracentesis;
      Gastrointestinal endoscopy with or without plans for biopsy, colonoscopy, polypectomy, or
      variceal banding; Liver biopsy; Bronchoscopy with or without plans for biopsy; Ablation
      therapy (radiofrequency ablation or ethanol ablation) or chemoembolization for HCC; Vascular
      catheterization and Transjugular intrahepatic portosystemic shunt.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of subjects who require platelet transfusion or rescue therapy for bleed after randomization ad up to 7 days after the elective procedure</measure>
    <time_frame>Approximately 20 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To confirm that avatrombopag (60 mg avatrombopag for subjects with platelet count less than 40 x 10^9/L and 40 mg avatrombopag for subjects with platelet count from 40 to less than 50 x 10^9/L) is superior to placebo in removing the need for platelet transfusions or any rescue procedure for bleeding after randomization and up to 7 days following an elective procedure in subjects with chronic liver disease who have thrombocytopenia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve a platelet counts &gt;= 50 x109/L on Procedure day</measure>
    <time_frame>Approximately 20 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To confirm that avatrombopag is superior to placebo in achieving a platelet count of greater than or equal to 50 x 109/L on Procedure Day in the proposed target population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of platelet counts on procedure day</measure>
    <time_frame>Up to approximately 20 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To confirm that avatrombopag is superior to placebo in elevating platelet counts from baseline on Procedure Day in the proposed target population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a WHO bleeding score &gt;= 2 after randomization and up to 7 days after an elective procedure</measure>
    <time_frame>Approximately 20 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate whether the observed incidence of bleeding in subjects treated with avatrombopag is noninferior to placebo in those subjects expected to receive a platelet transfusion prior to their procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of avatrombopag</measure>
    <time_frame>Approximately 20 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety assessments will consist of monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs), including platelet transfusion-related complications; routine laboratory evaluations.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Thrombocytopenia Associated With Liver Disease</condition>
  <arm_group>
    <arm_group_label>Group A (avatrombopag, lower baseline platelet count)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (placebo, lower baseline platelet count)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (avatrombopag, higher baseline platelet count)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D (placebo, higher baseline platelet count)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>avatrombopag (lower baseline platelet count)</intervention_name>
    <description>60 mg avatrombopag (3 x 20 mg tablets)</description>
    <arm_group_label>Group A (avatrombopag, lower baseline platelet count)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (lower baseline platlet count)</intervention_name>
    <description>60 mg placebo (3 x 20 mg matching placebo tablets)</description>
    <arm_group_label>Group B (placebo, lower baseline platelet count)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>avatrombopag (higer baseline platelet count)</intervention_name>
    <description>40 mg avatrombopag (2 x 20 mg tablets)</description>
    <arm_group_label>Group C (avatrombopag, higher baseline platelet count)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (higher baseline platelet count)</intervention_name>
    <description>40 mg placebo (2 x 20 mg matching placebo tablets)</description>
    <arm_group_label>Group D (placebo, higher baseline platelet count)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Subjects greater than or equal to 18 years of age at Screening with chronic liver
             disease

          2. Subjects who have a mean baseline platelet count of less than 50 x 109/L. Platelet
             counts must be measured on 2 separate occasions, during the Screening Period and at
             Baseline, and must be performed at least one day apart with neither platelet count
             greater than 60 x 109/L. The mean of these 2 platelet counts (mean baseline platelet
             count) will be used for entry criteria and for assignment to the low or high baseline
             platelet count cohort.

          3. Subjects scheduled to undergo a permitted elective procedure who, in the opinion of
             the investigator, will require a platelet transfusion to address a risk of bleeding
             associated with the procedure

          4. Model For End-stage Liver Disease (MELD) score less than or equal to 24 at Screening

          5. If taking inhibitors of P glycoprotein (P-gp), except for verapamil, dose must be
             stable for 7 days prior to Screening

          6. Provide written informed consent

          7. Willing and able to comply with all aspects of the protocol

        Exclusion Criteria

          1. Any history of arterial or venous thrombosis, including partial or complete
             thrombosis

          2. Evidence of thrombosis (partial or complete) in the main portal vein, portal vein
             branches, or any part of the splenic mesenteric system at Screening

          3. Adequate portal vein blood flow at Screening

          4. Hepatic encephalopathy that cannot be effectively treated

          5. Subjects with HCC with Barcelona Clinic Liver Cancer (BCLC) staging classification C
             or D

          6. Platelet transfusion or receipt of blood products containing platelets within 7 days
             of Screening. However packed red blood cells are permitted.

          7. Heparin, warfarin, nonsteroidal anti-inflammatory drugs (NSAID), aspirin, verapamil,
             and antiplatelet therapy with ticlopidine or glycoprotein IIb/IIIa antagonists (eg,
             tirofiban) within 7 days of Screening

          8. Use of erythropoietin stimulating agents within 7 days of Screening

          9. Interferon (IFN) use within 14 days of Screening

         10. Estrogen-containing hormonal contraceptive or hormone replacement therapy use within
             30 days of Screening

         11. Active infection requiring systemic antibiotic therapy within 7 days of Screening.
             However, prophylactic use of antibiotics is permitted.

         12. Alcohol abuse, alcohol dependence syndrome, drug abuse, or drug dependence within 6
             months of the study start (unless participating in a controlled rehabilitation
             program) or acute alcoholic hepatitis (chronic alcoholic hepatitis is allowed) within
             6 months of the study start

         13. Elective procedure performed prior to Visit 4 (Procedure Day)

         14. Known to be human immunodeficiency virus positive

         15. Any clinically significant acute or active bleeding (eg, gastrointestinal, central
             nervous system)

         16. Known history of any primary hematologic disorder (eg, immune thrombocytopenic
             purpura, myelodysplastic syndrome)

         17. Known medical history of genetic prothrombotic syndromes

         18. Subjects with a history of significant cardiovascular disease (eg, congestive heart
             failure New York Heart Association Grade III/IV, arrhythmia known to increase the
             risk of thromboembolic events [eg, atrial fibrillation], coronary artery stent
             placement, angioplasty, and coronary artery bypass grafting)

         19. Females of childbearing potential who have had unprotected sexual intercourse within
             30 days before study entry and who do not agree to use a highly effective method of
             contraception (eg, total abstinence, an intrauterine device, a double-barrier method
             [such as condom plus diaphragm with spermicide], a progesterone-only contraceptive
             implant/injection, or have a vasectomized partner with confirmed azoospermia)
             throughout the entire study period and for 30 days after study drug discontinuation.
             If currently abstinent, the subject must agree to use a double-barrier method as
             described above if she becomes sexually active during the study period or for 30 days
             after study drug discontinuation. All females will be considered to be of
             childbearing potential unless they are postmenopausal (at least 12 months consecutive
             amenorrhea in the appropriate age group and without other known or suspected cause)
             or have been sterilized surgically (ie, bilateral tubal ligation, hysterectomy, or
             bilateral oophorectomy) at least 1 month before dosing.

         20. Females who are lactating or pregnant at Screening or Baseline (as documented by a
             positive serum beta-human chorionic gonadotropin [B-hCG] test with a minimum
             sensitivity 25 IU/L or equivalent units of B-hCG). A separate baseline assessment is
             required if a negative screening pregnancy test was obtained more than 72 hours
             before the first dose of study drug.

         21. Post liver transplant subjects

         22. Any subject who has previously received avatrombopag

         23. Hypersensitivity to avatrombopag maleate or any of its excipients

         24. Hemoglobin levels less than or equal to 8.0 or greater than or equal to 16.0 g/dL at
             Screening

         25. White blood cell count less than or equal to 1.5 x 10^9/L or greater than or equal to
             15.0 x 10^9/L at Screening

         26. Serum sodium level less than or equal to 130 mEq/L at Screening

         27. Current malignancy including solid tumors and hematologic malignancies (except HCC)

         28. Any history of or concomitant medical condition that, in the opinion of the
             investigator(s), would compromise the subject's ability to safely complete the study

         29. Currently enrolled in another clinical trial or used any investigational drug or
             device within 30 days of Screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eisai Medical Services</last_name>
    <phone>1-888-422-4743</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pilar</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>msilva@cas.austral.edu.ar</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma Bs As</city>
        <state>Ciudad Autonoma Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>simone.strasser@sswahs.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>colombato@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>vdescalzi@ffavaloro.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>sanjeev.chunilal@southernhealth.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>christophe.moreno@erasme.ulb.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>luc.lasser@chu-brugmann.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>gfelga@einstein.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>chivim40@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>aheurgue@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>vleroy@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>nguyen-khac.eric@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>aabergel@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>buggisch@ifi-medizin.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>tgoeser-studien@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>a.leodolter@evk-herne.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>birke.bausch@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>spengler@uni-bonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>zeuzem@em.uni-frankfurt.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Vina del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>manns.michael@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <state>Bas Rhin</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>bhunyady@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble cedex 9</city>
        <state>Isere</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>langer.robert@med.semmelweis-univ.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Reims</city>
        <state>Marne</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>banyai@pandy.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Clermont Ferrand cedex 1</city>
        <state>Puy de Dome</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ifazekasi@freemail.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Amiens cedex 1</city>
        <state>Somme</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>vsl@pantaleon.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <state>Baden Wuerttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>a.dileo@gastro.uniba.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Herne</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>an.iacobellis@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Koeln</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>savino.bruno@fbf.milano.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>pietro.andreone@unibo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bekescsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>sghwang@cha.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>gvizzini@ismett.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>leeks519@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Dunaujvaros</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>yoonjh@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>vsavarin@unige.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jychoi@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>jheo@pusan.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>limys@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Foggia</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>lakmus@poczta.wprost.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>prieto_mar@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>m.jablkowski@pro.onet.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>mromerogomez@us.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>e.janczewska@poczta.fm</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>gloriasanchez_antolin@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>jturnesv@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam-Si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>norah.terrault@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>mchou@vghtpe.gov.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>matthew.brookes@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>lsher@health.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>yangss@tpts1.seed.net.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>kenneth.rothstein@drexelmed.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>sjoshi@ochsner.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Myslowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>sanchez.william@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>bonacim@sutterhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>sok9028@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Vila Real</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>charissa.chang@mountsinai.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>lorenzo.rossaro@ucdmc.ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>lakex009@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>guerreroj1@uthscsa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>apurva.modi@baylorhealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ratchathewi</city>
        <state>Bangkok</state>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Muang</city>
        <state>Chiang Mai</state>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Klongluang</city>
        <state>Pathum Thani</state>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Wolverhampton</city>
        <state>West Midlands</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>October 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Chronic Liver Disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
